Heterotopic breast tissue versus occult metastatic carcinoma in lymph node, a diagnostic dilemma.
Ann Diagn Pathol., Aug;14(4):260-3 (2010)
Higher levels of GATA3 predict better survival in women with breast cancer.
Hum. Pathol., Dec;41(12):1794-801 (2010)
Proteomic-based biosignatures in breast cancer classification and prediction of therapeutic response.
Int J Proteomics., 2011:896476 (2011)
Decreased expression of annexin A1 is correlated with breast cancer development and progression as determined by a tissue microarray analysis.
Hum. Pathol., Dec;37(12):1583-91 (2006)
Detection of breast cancer biomarkers in nipple aspirate fluid by SELDI-TOF and their identification by combined liquid chromatography-tandem mass spectrometry.
Int. J. Oncol., Jan;30(1):145-54 (2007)
Accuracy of clinical evaluation of locally advanced breast cancer in patients receiving neoadjuvant chemotherapy.
Cancer., Mar;115(6):1194-202 (2009)
Mass spectrometry (LC-MS/MS) site-mapping of N-glycosylated membrane proteins for breast cancer biomarkers.
J. Proteome Res., Aug;8(8):4151-60 (2009)
Tumor proteomic profiling predicts the susceptibility of breast cancer to chemotherapy.
Int. J. Oncol., Oct;35(4):683-92 (2009)
Differential response of triple-negative breast cancer to a docetaxel and carboplatin-based neoadjuvant treatment.
Cancer., Sep;116(18):4227-37 (2010)
Trastuzumab-based neoadjuvant therapy in patients with HER2-positive breast cancer.
Cancer., Jun;116(12):2856-67 (2010)
Outcomes and factors impacting local recurrence of ductal carcinoma in situ.
Cancer., Apr;88(7):1643-9 (2000)
Induction of MUC1-specific cellular immunity by a recombinant BCG expressing human MUC1 and secreting IL2.
Int. J. Oncol., Jun;20(6):1305-11 (2002)
Clinicopathologic analysis of sentinel lymph node mapping in early breast cancer.
Breast J., 9(3):153-62 (2003)
Proteomic profiling of cancer biomarkers.
Brief Funct Genomic Proteomic., Jul;2(2):147-58 (2003)
Loss of annexin A1 expression in human breast cancer detected by multiple high-throughput analyses.
Biochem. Biophys. Res. Commun., Jan;326(1):218-27 (2005)
In silico identification of breast cancer genes by combined multiple high throughput analyses.
Int. J. Mol. Med., Feb;15(2):205-12 (2005)
Do the histologic features and results of breast cancer biomarker studies differ between core biopsy and surgical excision specimens?
Breast., Apr;15(2):167-72 (2006)
Histopathologic characteristics predicting HER-2/neu amplification in breast cancer.
Breast J., 11(6):433-9 (2005)